Dermatol. praxi. 2025;19(3):108-112 | DOI: 10.36290/der.2025.020

Urticaria as a manifestation of Alpha-gal syndrome

MUDr. Tomáš Balner, doc. MUDr. Jaromír Bystroň, CSc.
Oddělení alergologie a klinické imunologie FN Ostrava, Ústav laboratorní medicíny, Lékařská fakulta, Ostravská univerzita v Ostravě

Chronic urticaria (CU) is a common and serious mast cell-mediated dermatological condition characterized by the development of pruritic wheals, angioedema, or both manifestations persisting for more than six weeks. The disease affects approximately 0,5-1% of the global population and significantly impairs patients' quality of life while generating substantial healthcare costs. Unlike acute urticaria, which typically resolves within six weeks, chronic urticaria presents specific diagnostic and therapeutic challenges requiring comprehensive understanding of its pathophysiology, classification, and management. The presented case report of alpha-gal syndrome emphasizes the importance of periodic reassessment of patients with long-standing "spontaneous" urticaria, as even apparently idiopathic cases may have an identifiable and treatable underlying cause.

Keywords: chronic urticaria, angioedema, alpha-gal syndrome, allergy.

Accepted: September 23, 2025; Published: October 2, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Balner T, Bystroň J. Urticaria as a manifestation of Alpha-gal syndrome. Dermatol. praxi. 2025;19(3):108-112. doi: 10.36290/der.2025.020.
Download citation

References

  1. Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA2LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy. 2009;64:1417-26. Go to original source... Go to PubMed...
  2. Greaves MW. Pathology and classification of urticaria. Immunol Allerg Clin. 2014;34:1-9. Go to original source... Go to PubMed...
  3. Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014;69:602-16. Go to original source... Go to PubMed...
  4. Antia C, Baquerizo K, Korman A, et al. Urticaria: A comprehensive review: Epidemiology, diagnosis, and work-up. J Am Acad Dermatol. 2018;79:599-614. Go to original source... Go to PubMed...
  5. Kolkhir P, Giménez-Arnau AM, Kulthanan K, et al. Urticaria. Nat Rev Dis Primers. 2022;8:61. Go to original source... Go to PubMed...
  6. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69:868-87. Go to original source... Go to PubMed...
  7. Weller K, Maurer M, Bauer A, et al. Epidemiology, comorbidities, and healthcare utilization of patients with chronic urticaria in Germany. J Eur Acad Dermatol Venereol. 2022;36:91-9. Go to original source... Go to PubMed...
  8. Sánchez-Borges M, Ansotegui IJ, Baiardini I, et al. The challenges of chronic urticaria part 1: Epidemiology, immunopathogenesis, comorbidities, quality of life, and management. World Allergy Organ J. 2021;14:100533. Go to original source... Go to PubMed...
  9. Toubi E, Kessel A, Avshovich N, et al. Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients. Allergy. 2004;59:869-73 Go to original source... Go to PubMed...
  10. Magerl M, Altrichter S, Borzova E, et al. The definition, diagnostic testing, and management of chronic inducible urticarias-the EAACI/GA2LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy. 2016;71:780-802. Go to original source... Go to PubMed...
  11. Maurer M, Fluhr JW, Khan DA. How to approach chronic inducible urticaria. J Allergy Clin Immunol Pract. 2018;6:1119-30. Go to original source... Go to PubMed...
  12. Kontou-Fili K, Borici-Mazi R, Kapp A, et al. Physical urticaria: classification and diagnostic guidelines. EAACI position paper. Allergy. 1997;52:504-13. Go to original source... Go to PubMed...
  13. Silpa-archa N, Kulthanan K, Pinkaew S. Physical urticaria: prevalence, type and natural course in a tropical country. J Eur Acad Dermatol Venereol. 2011;25:1194-9. Go to original source... Go to PubMed...
  14. Prosty C, Gabrielli S, Le M, et al. Prevalence, management, and anaphylaxis risk of cold urticaria: A systematic review and meta-analysis. J Allergy Clin Immunol Pract. 2022;10:586-96. Go to original source... Go to PubMed...
  15. Rujitharanawong C, Tuchinda P, Chularojanamontri L, et al. Cholinergic urticaria: clinical presentation and natural history in a tropical country. BioMed Res Int. 2020;2020:7301652. Go to original source... Go to PubMed...
  16. Abajian M, Schoepke N, Altrichter S, et al. Physical urticarias and cholinergic urticaria. Immunol Allergy Clin North Am. 2014;34:73-88. Go to original source... Go to PubMed...
  17. Dressler C, Werner RN, Eisert L, et al. Chronic inducible urticaria: a systematic review of treatment options. J Allergy Clin Immunol. 2018;141:1726-34. Go to original source... Go to PubMed...
  18. Boyden SE, Desai A, Cruse G, et al. Vibratory urticaria associated with a missense variant in ADGRE2. N Engl J Med. 2016;374:656-63. Go to original source... Go to PubMed...
  19. Beattie PE, Dawe RS, Ferguson J, et al. Solar urticaria: a report of 25 cases. Br J Dermatol. 2003;149:99-107.
  20. Hirschmann JV, Lawlor F, English JS, et al. Cholinergic urticaria. A clinical and histologic study. Arch Dermatol. 1987;123:462-7. Go to original source...
  21. Mathelier-Fusade P, Aissaoui M, Chabane MH, et al. Association of cold urticaria and aquagenic urticaria. Allergy. 1997;52:678-9. Go to original source... Go to PubMed...
  22. Fomina DS, Maltseva NP, Serdotetskova SA, et al. Epidemiology of chronic inducible urticaria in Moscow. Russian J Allergy. 2022;19:317-27. Go to original source...
  23. Church MK, Kolkhir P, Metz M, Maurer M. The role and relevance of mast cells in urticaria. Immunol Rev. 2018;282:232-47. Go to original source... Go to PubMed...
  24. Kaplan A, Lebwohl M, Giménez-Arnau AM, et al. Chronic spontaneous urticaria: focus on pathophysiology to unlock treatment advances. Allergy. 2023;78:389-401. Go to original source... Go to PubMed...
  25. Kay AB, Clark P, Maurer M, Ying S. Elevations in T-helper-2-initiating cytokines (interleukin-33, interleukin-25 and thymic stromal lymphopoietin) in lesional skin from chronic spontaneous ('idiopathic') urticaria. Br J Dermatol. 2015;172:1294-302. Go to original source... Go to PubMed...
  26. Kolkhir P, Church MK, Weller K, et al. Autoimmune chronic spontaneous urticaria: what we know and what we do not know. J Allergy Clin Immunol. 2017;139:1772-81. Go to original source... Go to PubMed...
  27. Asero R, Marzano AV, Ferrucci S, et al. Co-occurrence of IgE and IgG autoantibodies in patients with chronic spontaneous urticaria. Clin Exp Immunol. 2020;200:242-9. Go to original source... Go to PubMed...
  28. Kolkhir P, Elieh-Ali-Komi D, Metz M, et al. Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases. Nat Rev Immunol. 2022;22:294-308. Go to original source... Go to PubMed...
  29. Giménez-Arnau AM, DeMontojoye L, Asero R, et al. The pathogenesis of chronic spontaneous urticaria: the role of infiltrating cells. J Allergy Clin Immunol Pract. 2021;9:2195-208. Go to original source... Go to PubMed...
  30. Schoepke N, Doumoulakis G, Maurer M. Diagnosis of urticaria. Indian J Dermatol. 2013;58:211. Go to original source... Go to PubMed...
  31. Bernstein JA, Ziaie N, Criado R, et al. Chronic urticaria and angioedema: masqueraders and misdiagnoses. J Allergy Clin Immunol Pract. 2023;11:2251-63. Go to original source... Go to PubMed...
  32. Magerl M, Altrichter S, Borzova E, et al. The definition, diagnostic testing, and management of chronic inducible urticarias-the EAACI/GA2LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy. 2016;71:780-802. Go to original source... Go to PubMed...
  33. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77:734-66. Go to original source... Go to PubMed...
  34. Bonnekoh H, Jelden-Thurm J, Allenova A, et al. Urticarial vasculitis differs from chronic spontaneous urticaria in time to diagnosis, clinical presentation, and need for anti-inflammatory treatment: an international prospective UCARE study. J Allergy Clin Immunol Pract. 2023;11:2900-910. Go to original source... Go to PubMed...
  35. Kolkhir P, Elieh Ali Komi D, Canvin J, et al. Autoimmune chronic spontaneous urticaria. Allergy. 2021;76:2061-70.
  36. Del Pozzo-Magaña BR, Liy-Wong C. Drugs and the skin: A concise review of cutaneous adverse drug reactions. Br J Clin Pharmacol. 2022. doi:10.1111/bcp.15490. Go to original source... Go to PubMed...
  37. Gonçalo M, Giménez-Arnau A, Al-Ahmad M, et al. The global burden of chronic urticaria for the patient and society. Br J Dermatol. 2021;184:226-36. Go to original source... Go to PubMed...
  38. Kovalkova E, Fomina D, Borzova E, et al. Comorbid inducible urticaria is linked to non-autoimmune chronic spontaneous urticaria: CURE insights. J Allergy Clin Immunol Pract. 2024;12:482-90. Go to original source... Go to PubMed...
  39. Weller K, Groffik A, Church MK, et al. Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol. 2014;133:1365-72. Go to original source... Go to PubMed...
  40. Maurer M, Costa C, Gimenez Arnau A, et al. Antihistamine-resistant chronic spontaneous urticaria remains undertreated: 2-year data from the AWARE study. Clin Exp Allergy. 2020;50:1166-75. Go to original source... Go to PubMed...
  41. Zuberbier T, Bindslev-Jensen C, Canonica W, et al. EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy. 2006;61:321-31. Go to original source... Go to PubMed...
  42. Siebenhaar F, Staubach P, Metz M, et al. High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. J Allergy Clin Immunol. 2009;123:672-9. Go to original source... Go to PubMed...
  43. Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368:924-35. Go to original source... Go to PubMed...
  44. Rutkowski K, Grattan CEH. How to manage chronic urticaria 'beyond' guidelines: a practical algorithm. Clin Exp Allergy. 2017;47:710-8. Go to original source... Go to PubMed...
  45. Rudenko M, Patel D, Kaplan A, et al. Remibrutinib in chronic urticaria: a comprehensive review of efficacy, safety and mechanisms of action. Clin Rev Allergy Immunol. 2023;64:328-39.
  46. Simpson EL, Bieber T, Guttman-Yassky E, et al. Two Phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375:2335-48. Go to original source... Go to PubMed...
  47. Maurer M, Metz M, Anderson J, et al. Barzolvolimab demonstrates clinical activity in a multiple ascending dose trial in chronic spontaneous urticaria. EAACI Congress 2023; June 9-11.
  48. Metz M, Maurer M. Use of biologics in chronic spontaneous urticaria-beyond omalizumab therapy? Allergol Select. 2021;5:89-95. Go to original source... Go to PubMed...
  49. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose. N Engl J Med. 2008;358:1109-17. Go to original source... Go to PubMed...
  50. Platts-Mills TAE, Li RC, Keshavarz B, et al. Diagnosis and management of patients with the α-Gal syndrome. J Allergy Clin Immunol Pract. 2019. doi:10.1016/j.jaip.2019.09.017. Go to original source... Go to PubMed...
  51. Commins SP. Diagnosis & management of Alpha-gal Syndrome: Lessons from 2,500 patients. Expert Rev Clin Immunol. 2020. doi:10.1080/1744666X.2020.1782745. Go to original source... Go to PubMed...




Dermatology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.